Heat shock proteins in cancer: Targeting the 'chaperones

Future Medicinal Chemistry

Volumn 4, Issue 7, 2012, Pages 927-935

  Nahleh, Z ^a   Tfayli, A ^b   Najm, A ^c   El Sayed, A ^d   Nahle, Z ^e  

^a Texas Tech University Health Sciences Center El Paso   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Memorial Medical Center   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK PROTEIN INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

CANCER CELL; CANCER CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; DRUG TARGETING; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84861088675     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.50     Document Type: Review

References (95)

1. Richter K, Haselbeck M, Buchner J. The heat shock response: Life on the verge of death. Mol. Cell 40(2), 253-266 (2010
2. Almeida M, Nascimento JL, Herculano AM, Crespo-Lopez ME. Molecular chaperones: Toward new therapeutic tools. Biomed. Pharmacother. 65, 239-243 (2011
3. Young D, Agashe VR, Siegers K, Hartl F. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol. 5, 781-791 (2004
4. Wang W, Vinocur B, Shoseyov O, Altman A. Role of plant heat-shock proteins and molecular chaperones in the abiotic stress response. Trends Plant Sci. 9(5), 244-252 (2004
5. Soti C, Nagy E, Giricz Z, Vigh L, Csermely P, Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br. J. Pharmacol. 146(6), 769-780 (2005
6. Laudanski K, Wyczechowska D. The distinctive role of small heat shockproteins in oncogenesis. Arch. Immunol. Ther. Exp. (Warsz). 54(2), 103-111 (2006
7. Wegele H, Muller L, Buchner J. Hsp70 and Hsp90 - A relay team for protein folding. Rev. Physiol. Biochem. Pharmacol. 151, 1-44 (2004
8. Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 75, 271-294 (2006
9. Bruey JM, Ducasse C, Bonniaud P et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat. Cell Biol. 2, 645-652 (2000
10. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: Anti-Apoptotic proteins with tumorigenic properties. Cell Cycle 5, 2592-2601(2006
11. Ravagnan L, Gurbuxani S, Susin SA et al. Heat-shock protein 70 antagonizes apoptosis- inducing factor. Nat. Cell Biol. 3, 839-843 (2001
12. Lanneau D, de Thonel A, Maurel S, Didelot C, Garrido C. Apoptosis versus cell differentiation: Role of heat shock proteins Hsp90, Hsp70 and Hsp27. Prion 1(1), 53-60 (2007
13. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130(6) 1005-1018 (2007
14. Bagatell R, Paine-Murrieta GD, Taylor CW et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin. Can. Res. 6(8), 3312-3318 (2000
15. Baler R, Zou J, Voellmy R. Evidence for a role of Hsp70 in the regulation of the heat shock response in mammalian cells. Cell Stress Chaperones 1(1), 33-39(1996
16. Mosser DD, Duchaine J, Massie B. The DNA-binding activity of the human heat shock transcription factor is regulated in vivo by Hsp70. Mol. Cell. Biol. 13(9), 5427-5438 (1993
17. Cheng L, Hirst K, Piper PW. Authentic temperature-regulation of a heat shock gene inserted into yeast on a high copy number vector. Influences of overexpression of Hsp90 protein on high temperature growth and thermotolerance. Biochim. Biophys. Acta 1132(1), 26-34 (1992
18. Hjorth-Sorensen B, Hoffmann ER, Lissin NM, Sewell AK, Jakobsen BK. Activation of heat shock transcription factor in yeast is not influenced by the levels of expression of heat shock proteins. Mol. Microbiol. 39(4), 914-923(2001
19. Soti C, Csermely P. Aging and molecular chaperones. Exp. Gerontol. 38(10), 1037-1040 (2003
20. HarrisN, MacLean M, Hatzianthis K, Panaretou B, Piper PW. Increasing Saccharomyces cerevisiae stress resistance, through the overactivation of the heat shock response resulting from defects in the Hsp90 chaperone, does not extend replicative life span but can be associated with slower chronological aging of nondividing cells. Mol. Genet. Genomics 265(2), 258-263(2001
21. Hooper PL. Hot-Tub therapy for Type 2 diabetes mellitus. N. Engl. J. Med. 341(12), 924-925 (1999
22. Hooper PL, Hooper PL. Inflammation, heat shock proteins, and Type 2 diabetes. Cell Stress Chaperones 14(2), 113-115 (2009
23. Romanucci M, Bastow T,Della Salda L. Heat shock proteins in animal neoplasms and human tumors - A comparison. Cell Stress Chaperones 13(3), 253-262(2008
24. Sankhala KK, Mita MM, Mita AC, Takimoto CH. Heat shock proteins: A potential anticancer target. Curr. Drug Targets 12(14), 2001-2008 (2011
25. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10(2), 86-103 (2005
26. Soo ET, Yip GW, Lwin ZM, Kumar SD, Bay BH. Heat shock proteins as novel therapeutic targets in cancer. In Vivo 22(3), 311-315 (2008
27. Calderwood SK, Khaleque MA, Sawyer DB, CioccaDR. Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem. Sci. 31(3), 164-172 (2006
28. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med.228(2), 111-133 (2003
29. Shiota M, Kusakabe H ,Yzumi Y,et al. Heat shock cognate protein 70 is essential for Akt signaling in endothelial function. Arterioscler. Thromb. Vasc. Biol. 30(3), 491-497 (2010
30. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA. Biological and clinical implications of heat shock protein 27,000 (Hsp27): A review. J. Natl Cancer Inst. 85, 1558-1570 (1993
31. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: Anti-Apoptotic proteins with tumorigenic properties. Cell Cycle 5, 2592-2601 (2006
32. Takayama S, Reed JCand Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 22, 9041-9047 (2003
33. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic Hsp90 complex in cancer. Nat. Rev. Cancer. 10(8), 537-549 (2010
34. Eiseman JL, Lan J, Lagattuta TF et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2- dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol. 55, 21-32 (2005
35. Chandarlapaty S, Scaltriti M, Angelini P et al. Inhibitors of Hsp90 block p95-HER2 signaling in trastuzumab-resistant tumors and suppress their growth. Oncogene 29, 325-334 (2010
36. Kim YS, Alarcon SV, Lee S et al. Update of Hsp90 inhibitors in clinical trial. Curr. Top. Med. Chem. 9(15), 1479-1492 (2009
37. Landriscina M, Amoroso MR, Piscazzi A, Esposito F. Heat shock proteins, cell survival and drug resistance: The mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. Gynecol. Oncol. 117(2), 177-182 (2010
38. Sreedhar AS, Kalmár E, Csermely P, Shen YF. Hsp90 isoforms: Functions, expression and clinical importance. FEBS Lett. 562, 11-15 (2004
39. McClellan AJ, Xia Y, Deutschbauer AM, Davis RW, Gerstein M, Frydman J. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 131, 121-135 (2007
40. Eustace BK, Sakurai T, Stewart JK et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell Biol. 6, 507-514 (2004
41. Whitesell L, Lindquist SL. Hsp90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761-772 (2005
42. Pick E, Kluger Y, Giltnane JM et al. High Hsp90 expression is associated with decreased survival in breast cancer. Cancer Res. 67, 2932-2937 (2007
43. Price JT, Quinn JM, Sims NA et al. The heat shock protein 90 inhibitor, 17-Allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res. 65, 4929-4938 (2005
44. Roe S, Prodromou C, O'Brien R,Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by antitumor antibiotic radicicol and geldanamycin. J. Med. Chem. 42(2), 260-266 (1999
45. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 36, 305-315 (1995
46. Stebbins CE, Russo AA, Schneider C et al. Crystal structure of an Hsp90-geldanamycin complex. Cell 89(2), 239-250 (1997
47. Donnelly A, Blagg BS. Novobiocin and additional inhibitors of the Hsp90 C-Terminal nucleotide binding pocket. Curr. Med. Chem. 15(26), 2702-2717 (2009
48. Lancet E, Gojo I, Burton M et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 24, 699-705 (2010
49. Kummar S, Gutierrez ME, Gardner ER et al. Phase I trial of 17-dimethylaminoethylamino- 17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur. J. Cancer 46, 340-347 (2010
50. Hanson BE, Vesole DH. Retaspimycin hydrochloride (IPI-504): A novel heat shock protein inhibitor as an anticancer agent. Expert Opin. Investig. Drugs 18, 1375-1383 (2009
51. Shelton S.N. Shawgo ME, Matthews SB et al. A novel Novobiocin-derived C-Terminal inhibitor of the 90-kDa heat shock protein exerts potent antiproliferative effects in human leukemic cells. Mol. Pharmacol. 76(6), 1314-1322 (2009
52. Lundgren K, Zhang H, Brekken J et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol. Cancer Ther. 8, 921-929 (2009
53. Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, Shores CG. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int. J. Cancer 126, 1216-1225 (2010
54. Zhang H, Neely L, Lundgren K et al. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int. J. Cancer 126, 1226-1234 (2010
55. Elfiky A, Saif MW, Beeram M et al. BIIB021, an oral, synthetic non-Ansamycin Hsp90 inhibitor: Phase I experience. J. Clin. Oncol. 26, 127-129 (2008
56. Cerchietti LC, Lopes EC, Yang SN et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6 dependent B cell lymphomas. Nat. Med. 15(12), 1369-1376 (2009
57. Sharp SY, Prodromou C, Boxall K et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylicpyrazole/isoxazole amide analogues. Mol. Cancer Ther. 6, 1198-1211 (2007
58. Eccles SA, Massey A, Raynaud FI et al. NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 68, 2850-2860 (2008
59. Jensen MR, Schoepfer J, Radimerski T et al. NVP-AUY922: A small molecule Hsp90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 10(2), R33 (2008
60. Chandarlapaty S, Sawai A, Ye Q et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin. Cancer Res. 14, 240-248 (2008
61. Wang Y, Trepel JB, Neckers LM, Giaccone G. STA-9090, a small-mulecule Hsp90 inhibitor for the potential treatment of cancer. Curr. Opin. Investig. Drugs. 11(12), 1466-1476 (2010
62. Proia DA, Foley KP, Korbut T et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS ONE 6(4), e18552 (2011
63. Yu MK, Samlowski WE, Baichwal V. MPC-3100, a fully synthetic, orally bioavailable Hsp90 inhibitor, in cancer patients. Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
64. Young JC, Barral JM, Ulrich Hartl F. More than folding: Localized functions of cytosolic chaperones. Trends Biochem. Sci. 28, 541-547 (2003
65. Chiang HL, Terlecky SR, Plant CP, Dice JF. A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science 246, 382-385 (1989
66. GalluzziL, Giordanetto F, Kroeme G. Targeting Hsp70 for cancer therapy. Mol. Cell. 36(2), 176-177 (2009
67. Pei H, Zhu H, Zeng S, Li Y, Yang H. Proteome analysis and tissue micro array for profiling protein markers associated with lymph node metastasis in colorectal cancer. J. Proteome Res. 6(7), 2495-2501 (2007
68. Jaattela M. Over-expression of hsp70 confers tumorigenicity to mouse fibrosarcoma cells. Int. J. Cancer 60, 689-693 (1995
69. Brondani Da Rocha A, Regner A, Grivicich I et al. Radioresistance is associated to increased Hsp70 content in human glioblastoma cell lines. Int. J. Oncol. 25, 777-785 (2004
70. Schmitt E, Parcellier A, Gurbuxani S et al. Chemosensitization by a non-Apoptogenic heat shock protein 70-binding apoptosis-inducing factor mutant. Cancer Res. 63, 8233-8240 (2003
71. Gabai VL, Meriin AB, Yaglom JA, Volloch VZ, Sherman MY. Role of Hsp70 in regulation of stress-kinase JNK: Implications in apoptosis and aging. FEBS Lett. 438, 1-4 (1998
72. Bottoni P, Giardina B, Scatena R. Proteomic profiling of heat shock proteins: An emerging molecular approach with direct pathophysiological and clinical implications. Proteomics Clin Appl. 3, 636-653 (2009
73. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and Hsp72 inhibits Hsp90 function and induces tumor-specific apoptosis. Cancer Cell. 14, 250-262 (2008
74. Powers MV, Clarke PA, Workman P. Death by chaperone,Hsp90, Hsp70 or both? Cell Cycle 8, 518-526 (2009
75. Braunstein MJ, Scott SS,Scott CM et al.Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101. J. Oncol. 201, 232037 (2011
76. Parcellier A, Schmitt E, Gurbuxani S et al. Hsp27 is a ubiquitin-binding protein involved in I-kBa proteasomal degradation. Mol. Cell. Biol. 23, 5790-5802 (2003
77. Rocchi P, Kojima S, Signaevsky M et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 64, 6595-6602 (2004
78. Garrido C, Fromentin A, Bonnotte B et al. Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res. 58, 5495-5499 (1998
79. Williams K, Chubb C, Huberman E, Giometti CS. Analysis of differential protein expression in normal and neoplastic human breast epithelial cell lines. Electrophoresis. 19, 333-343 (1998
80. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S et al. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int. J. Oncol. 31, 1345-1350 (2007
81. Choi DH, Ha JS, Lee WH et al. Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells. FEBS Lett. 581, 1649-1656 (2007
82. Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG, Fuqua SA. Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res. Treat. 56, 187-196 (1999
83. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by Hsp90 (Hsp90 complex) that forms a stress-sensitive complex with HSF1. Cell 94, 471-480 (1998
84. Piper PW,MillsonSH. Mechanisms of resistance to Hsp90 inhibitor drugs: A complex mosaic emerges. Pharmaceuticals 4, 1400-1422 (2011
85. Davenport EL, Zeisig A, Aronson LI et al. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia 24, 1804-1807 (2010
86. Rossi A, Ciafrè S, Balsamo M, Pierimarchi P, Santoro MG. Targeting the heat shock factor 1 by RNA interference: A potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. Cancer Res. 66(15), 7678-7685 (2006
87. Murshid A, Chou SD, Prince T, Zhang Y, Bharti A, Calderwood SK. Protein kinase A binds and activates heat shock factor 1. PLoS ONE 5, e13830 (2010
88. Akerfelt M, Morimoto RI, Sistonen L. Heat shock factors: Integrators of cell stress, development and lifespan. Nat. Rev. Mol Cell. Biol. 11, 545-555 (2010
89. Kang BH, Altieri DC. Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Oncogene 28, 3681-3688 (2009
90. Kang BH, Plescia J, Song HY et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest. 119(3), 454-464 (2009
91. Kamal A, Thao L, Sensintaffar J et al. A high-Affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407-410 (2003
92. Gallo LI, Lagadari M, Piwien-Pilipuk G, Galigniana MD. The 90-kDa heat-shock protein (Hsp90)-binding immunophilin FKBP51 is a mitochondrial protein that translocates to the nucleus to protect cells against oxidative stress. J. Biol. Chem. 286(34), 30152-30160 (2011
93. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: Repercussions in cancer therapy. J. Leukoc. Biol. 81, 15-27 (2007
94. Mazzaferro V, Coppa J, Carrabba MG et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. 9, 3235-3245 (2003
95. Castelli C, Rivoltini L, Rini F et al. Heat shock proteins: Biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol. Immunother. 53, 227-233 (2004).